Rebetron

Rebetron®

Virology An antiviral that combines Rebetol®–ribavirin and Intron® A–recombinant IFN alfa-2b injection for treating chronic HCV in Pts with compensated liver disease. See Hepatitis C virus, Interferon.
References in periodicals archive ?
Prior to that, he served as Clinical Director in the Department of Hepatology/Gastroenterology at Schering Plough where he was medical lead on the pediatric sNDA for Rebetron for chronic HCV.
7% Protocol follows standards approved by the department TEXAS Yes Unknown Determined by university providers UTAH Yes Unknown Inmates may apply for inter- feron review and treatment if they meet established prison criteria; A and B immuniza- tions are given to all hepatitis C-reactive inmates VERMONT VIRGINIA No 5% Drug therapy for those who meet established criteria WASHINGTON Yes 17% Typically given rebetron but will use interferon for those who meet specific criteria WEST VIRGINIA WISCONSIN Yes 13.
Schering-Plough's United States alpha interferon products include INTRON A (interferon alfa-2b, recombinant) Injection; PEG-INTRON (peginterferon alfa-2b) Powder for Injection; and REBETRON Combination Therapy containing REBETOL (ribavirin, USP) Capsules and INTRON A.
These earnings reflect the successful launch of the new combination of PEG-Intron-Rebetol in the US and Europe and the launch of Rebetron combination treatment in Japan by our partner, Schering-Plough," said Johnson Y.
The FDA encourages health care providers to report pregnancies in women on Rebetol or the sexual partners of men on Rebetol to the Rebetron Pregnancy Registry at 800-727-7064.
Schering-Plough has reported it will continue to market REBETRON Combination Therapy in the United States.
Manufactured by Schering-Plough Corporation, Rebetron is a combination of the drugs Rebetol (ribavirin), a capsule, and Intron (interferon alpha-2b recombinant), an injection.
Schering-Plough Corporation, Madison, NJ, announced the US Food and Drug Administration (FDA) has approved Rebetron Combination Therapy containing Rebetol (ribavirin, USP) capsules and Intron A (interferon alfa-2b, recombinant) injection for the treatment of hepatitis C in patients with compensated liver disease previously untreated with alpha interferon therapy.
Under his stewardship, Schering Labs created and developed important prescription therapeutic markets ranging from non-sedating antihistamines (Claritin and Clarinex) to the successful treatment of Hepatitis-C (Intron-A, Rebetron, and Peg-Intron).
Currently, ribavirin is not marketed separately and is packaged only in combination with Intron A and marketed as Rebetron.
The Intron franchise includes the anticancer/antiviral agent Intron A Injection, as monotherapy and in combination with Rebetol Capsules for treating hepatitis C; Peg-Intron Powder for Injection, a longer-acting form of Intron A, as monotherapy and in combination with rebetol for treating hepatitis C; and Rebetron Combination Therapy containing Intron A and Rebetol.